Disease Domain | Count |
---|---|
Nervous System Diseases | 8 |
Immune System Diseases | 3 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 6 |
Diagnostic radiopharmaceuticals | 5 |
Synthetic peptide | 1 |
Target |
Mechanism GSK-3β inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism GRIA2 modulators |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Mechanism D1 receptor modulators [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 Jan 2026 |
Sponsor / Collaborator |
Start Date01 Sep 2025 |
Sponsor / Collaborator [+5] |
Start Date15 May 2025 |
Sponsor / Collaborator ![]() [+5] |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
I-105 ( D1 receptor x D2 receptor ) | Depressive Disorder More | Preclinical |
ZCAN155 ( GRIA2 ) | Multiple Sclerosis More | Preclinical |
YH668 ( GRIA2 ) | Multiple Sclerosis More | Preclinical |
[11C]RO-6899880 ( GABA receptor ) | Alzheimer Disease More | Preclinical |
[18F]OXD-2314 ( TAU ) | Tauopathies More | Preclinical |